Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Topos Bio Secures $10.5M to Tackle ‘Undruggable’ Proteins Driving Alzheimer’s and Cancer
Founded by Berkeley and Stanford researchers, Topos Unveils Breakthrough Foundation Model for Disordered Proteins and Partnering with Gladstone Institutes
Topos Bio, a biotechnology company pioneering AI-driven drug discovery for intrinsically disordered proteins (IDPs), today emerged from stealth with $10.5M in seed funding from Boldstart, Threshold, and Neo, with participation from notable angel investors including Dara Khosrowshahi (CEO at Uber) and Naveen Rao (CEO at Unconventional AI). The company is also releasing a technology report demonstrating state-of-the-art performance of its AI model on this challenging protein class.
The Problem: Drugging the Undruggable
Traditional drug discovery relies on the “lock-and-key” model: proteins fold into stable 3D structures, and drugs are designed to fit precisely into their binding pockets. Intrinsically disordered proteins (IDPs) break this paradigm entirely. Rather than adopting a single fixed shape, IDPs rapidly fluctuate through many different conformations. Without stable binding pockets, traditional drugs have nowhere to anchor. Current computational tools fail here because they predict static structures, not dynamic ensembles of constantly shifting shapes. This leaves roughly one-third of the human proteome – including the primary drivers of Alzheimer’s, Parkinson’s, and many aggressive cancers – effectively undruggable by conventional methods.
“Disordered proteins represent one of the last major frontiers in drug discovery – they’re central to devastating diseases but nearly impossible to target with existing methods,” said Ryan Zarcone, Co-Founder and CEO at Topos Bio. “Our platform tackles this by modeling protein dynamics as ensembles rather than static structures. This approach enables rational drug design and opens up an entirely new category of previously undruggable biology.”
Topos Bio’s Solution: Frontier AI for Disordered Proteins
Topos Bio has developed an AI-native integrated discovery platform specifically designed for intrinsically disordered proteins. The company’s AI models generate ensembles that capture how these proteins fluctuate through millions of conformations, then identify binding opportunities within these dynamic structures. Using generative chemistry, the platform designs small molecules optimized to modulate these disordered regions…
Full release here, originally announced January 8th, 2026.
Oasys Raises $4.6M to Transform Mental Health Care into a Data-Driven Discipline, Catalyzing Better Health Outcomes
The Company’s AI-Native Operating System Unifies Practice Management, Clinical Decision Support, and Real-Time Physiological Data to Improve Therapist and Patient Well-Being
Oasys Health, the first AI-native operating system for behavioral health, today announces $4.6M in funding, including a $4M seed round led by Pathlight Ventures, with participation from Twine Ventures and Better Ventures, and $600K in pre-seed funding from 1984 Ventures. As demand for mental health support surges, Oasys will use new capital to enhance its AI-powered platform, deepen integrations with leading wearables and health apps, grow its engineering and data science teams, and expand its network of partnerships with health clinics, behavioral health centers, Managed Service Organizations (MSOs), and universities and schools investing in long-term campus mental health infrastructure.
“Our momentum at Oasys reflects a fundamental turning point for mental health care, where data and AI empower, rather than replace, clinicians,” said Hashem Abdou, Co-Founder and CEO at Oasys. “For decades, therapy has been a subjective, session-based practice built on intuition and recall rather than measurable evidence. Now, for the first time, we have the tools to change that. Advances in AI allow us to extract insights from unstructured clinical data, the explosion of wearables gives us continuous behavioral and physiological insight, and Oasys has built the connective tissue to tie it all together. This funding advances our mission to redefine how we clinically care for mental health by creating the operating system that makes care personalized, data-driven, and accessible to all.”
The Mental Health Crisis is Growing & Outdated Systems Can’t Address It
The world faces record levels of anxiety, depression, and burnout—yet the systems designed to deliver mental health care are outdated, disconnected, and reactive. While other areas of medicine have embraced data, automation, and continuous monitoring, mental health remains largely analog. Clinicians are forced to operate in silos and are overburdened by administrative work—and existing tools fail to support their workflows because they were built for billing, not care. As a result, patients are treated episodically, often seeking help only once symptoms reach a breaking point, and progress can’t be measured in real time.
Oasys exists to close that gap, bringing the same level of clinical precision, operational intelligence, and data integration to mental health that modern medicine applies to the body…
Full release here, originally announced January 7th, 2026.
No comments:
Post a Comment